New Kids on the Block: Estimating Use of Next-generation Gram-negative Antibiotics Across Greater Than 700 Hospitals in the United States.

ABSTRACT:

Background

In recent years, new broad-spectrum antibiotics targeting Gram-negative organisms have been introduced, including cefiderocol, ceftazidime-avibactam, ceftolozane-tazobactam, eravacycline, imipenem-relebactam, omadacycline, and meropenem-vaborbactam. This study aimed to describe new antibiotic use across a large national cohort.

Methods

We performed a retrospective cohort study of hospital discharges from June 2022 to May 2023 using the Premier Healthcare Database. Antibiotic utilization was ascertained from daily charges. Clinical indication(s) were inferred from International Classification of Diseases, 10th revision, diagnosis codes. Antibiotic therapy was considered definitive if continued >3 days. Piperacillin-tazobactam was used as a comparator.

Results

SUBMITTER: Harris AD 

PROVIDER: S-EPMC11878548 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature